SIGLEC17P

Across TCGA pan-cancer cohorts, SIGLEC17P RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated SIGLEC17P data layer.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SIGLEC17P RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated SIGLEC17P expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and BRCA are the cancer types where SIGLEC17P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.755	0.634	<.001	142	view →
LUAD	OS	Tertile	All	0.467	0.319	<.001	66	view →
BRCA	OS	Tertile	All	0.984	0.945	<.001	66	view →
CHOL	DFS	Tertile	All	0.704	0.108	<.001	60	view →
KIRC	OS	Tertile	All	0.903	0.851	.004	55	view →
KIRP	OS	Tertile	III,IV	0.214	0.940	.004	53	view →
ACC	DFS	Median	All	0.758	0.423	<.001	41	view →
UCEC	DFS	Tertile	IV	0.822	0.415	.012	36	view →
SARC	OS	Median	All	0.825	0.661	<.001	22	view →
COAD	OS	Median	IV	0.828	0.418	.020	15	view →
OV	OS	Tertile	All	0.277	0.356	.017	12	view →
STAD	DFS	Quartile	All	0.569	0.701	.030	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

SIGLEC17P–HNSC (DFS)

Open the HNSC breakdown →